Protected PCI

Patient Identification

A venn diagram showing the appropriate population for a Protected PCI with Impella

Which Patients May Benefit from Protected PCI?

Impella® heart pumps may provide safe and effective hemodynamic support in elective and urgent high-risk PCI for a broad range of patients with complex coronary artery disease, hemodynamic compromise and comorbidities.

Patients benefit from this minimally invasive option that may:

  • Enable more complete revascularization1
  • Reduce symptoms and class of heart failure2 and improve LVEF1
  • Significantly reduce the overall incidence of post-procedural acute kidney injury (AKI)5
  • Reduce number of days in the hospital3,4
  • Significantly reduce post-discharge MACCE events (composite of death/stroke/MI/repeat revascularization)6
Graph showing that surgical ineligibity is associated with higher mortality

Surgical Turndown is Common and Associated with Higher Mortality

Protected PCI may be an option when surgery is not. Consider Protected PCI for patients who are considered too high-risk and therefore turned down for surgery, and for patients who decline surgical treatment.

Underdiagnosed & Undertreated

Chart showing the underdiagnosed and undertreated population of patients
Many patients with severe, symptomatic CAD remain untreated or undertreated due to comorbidities, increased risk of AKI or hemodynamic compromise.
 

Impella-Supported Nonemergent High-risk PCI

Samin Sharma, MD, discusses his algorithm for selecting patients for high-risk PCI.

Resources from the Education Library

 

High-Risk PCI in the COVID-19 Era

Shami Mahmud, MD, explains how his institution continues to perform high-risk interventions during COVID-19.

 

LVEF Improvement After Complex CHIP Case with Impella Support

Rustem Dautov, MD, presents the case of a patient turned down for surgery and successfully treated with Impella CP®.

 

High-Risk PCI with Impella Support and Atherectomy

Thom Dahle, MD, presents the case of an 84-year-old with a history of CAD with prior stenting of the circumflex. In this case, the patient is his father.

 

 

 

Clinical Evidence

Read extensive data, including RCT findings and a published literature review of 3,301 patients, that supports Impella® safety and efficacy.

References

  1. Burzotta, F., et al. (2019). J Interv Cardiol, 2019(5):1-10.

  2. O’Neill, W.W., et al. (2012). Circulation, 126(14), 1717-1727.

  3. Gregory, D., et al. (2013). Am Health Drug Benefits, 6(2), 88-99.

  4. Maini, B., et al. (2014). Expert Rev Pharmacoecon Outcomes Res, 14(3), 403-416.

  5. Flaherty, M.P., et al. (2017). Circ Res, 120(4), 692-700.
  6. Dangas, G.D., et al. (2014). Am J Cardiol, 113(2), 222-228.

NPS-1180